Akiko Hisamoto

592 total citations
25 papers, 464 citations indexed

About

Akiko Hisamoto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Akiko Hisamoto has authored 25 papers receiving a total of 464 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Akiko Hisamoto's work include Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Research Studies (9 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Akiko Hisamoto is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Research Studies (9 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Akiko Hisamoto collaborates with scholars based in Japan. Akiko Hisamoto's co-authors include Mitsune Tanimoto, Katsuyuki Kiura, Katsuyuki Hotta, Masahiro Tabata, Toshiyuki Kozuki, Nagio Takigawa, Hiroshi Ueoka, Keiichi Fujiwara, Toshiaki Okada and Eiki Ichihara and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Akiko Hisamoto

23 papers receiving 453 citations

Peers

Countries citing papers authored by Akiko Hisamoto

Since Specialization

Citations

This map shows the geographic impact of Akiko Hisamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akiko Hisamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akiko Hisamoto more than expected).

Fields of papers citing papers by Akiko Hisamoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akiko Hisamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akiko Hisamoto. The network helps show where Akiko Hisamoto may publish in the future.

Co-authorship network of co-authors of Akiko Hisamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Akiko Hisamoto. A scholar is included among the top collaborators of Akiko Hisamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akiko Hisamoto. Akiko Hisamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of a Cyclooxygenase-2 Inhibitor in Combination with (-)-Epigallocatechin Gallate or Polyphenon E on Cisplatin-Induced Lung Tumorigenesis in A/J Mice. 2023 ·PubMed ·Ken Sato, Nagio Takigawa, Toshio Kubo, Hideki Katayama, Daizo Kishino, Toshiaki Okada, Akiko Hisamoto, (unknown), Nobuaki Ochi, (unknown), Hiroshi Ueoka, Mitsune Tanimoto, (unknown), Katsuyuki Kiura	1
2	Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803 2014 ·Journal of Thoracic Oncology ·Akira Inoue, Shunichi Sugawara, Masao Harada, Kunihiko Kobayashi, Toshiyuki Kozuki, Shoichi Kuyama, Makoto Maemondo, Hajime Asahina, Akiko Hisamoto, Taku Nakagawa, Katsuyuki Hotta, Toshihiro Nukiwa	28
3	A Definite Case of <sub>L</sub>-carbocisteine-induced Pneumonia with CATCH22 Syndrome 2013 ·Internal Medicine ·Kenichiro Kudo, Eiki Ichihara, Akiko Hisamoto, Katsuyuki Hotta, Nobuaki Miyahara, Yasushi Tanimoto, (unknown), Katsuya Kato, Mitsune Tanimoto, Katsuyuki Kiura	2
4	Phase II study of amrubicin (AMR) and carboplatin (CBDCA) for invasive thymoma (IT) and thymic carcinoma (TC): NJLCG0803. 2013 ·Journal of Clinical Oncology ·Yosuke Kawashima, Akira Inoue, Shunichi Sugawara, Masao Harada, Kunihiko Kobayashi, Toshiyuki Kozuki, Shoichi Kuyama, Tomohiro Sakakibara, Makoto Maemondo, Hajime Asahina, Akiko Hisamoto, Taku Nakagawa, Toshihiro Nukiwa	6
5	Synergistic Effect of Olaparib with Combination of Cisplatin on PTEN -Deficient Lung Cancer Cells 2012 ·Molecular Cancer Research ·Daisuke Minami, Nagio Takigawa, (unknown), Minoru Takata, Nobuaki Ochi, Eiki Ichihara, Akiko Hisamoto, Katsuyuki Hotta, Mitsune Tanimoto, Katsuyuki Kiura	50
6	Influence of the timing of tumor regression after the initiation of chemoradiotherapy on prognosis in patients with limited-disease small-cell lung cancer achieving objective response 2012 ·Lung Cancer ·Masanori Fujii, Katsuyuki Hotta, Nagio Takigawa, Akiko Hisamoto, Eiki Ichihara, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura	7
7	Treatment-Related Death in Patients with Small-Cell Lung Cancer in Phase III Trials over the Last Two Decades 2012 ·PLoS ONE ·Nobuaki Ochi, Katsuyuki Hotta, Nagio Takigawa, Isao Oze, Yoshiro Fujiwara, Eiki Ichihara, Akiko Hisamoto, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura	11
8	A phase II trial of induction gefitinib monotherapy followed by cisplatin-docetaxel and concurrent thoracic irradiation in patients with EGFR-mutant locally advanced non-small-cell lung cancer (LA-NSCLC): LOGIK0902/OLCSG0905 intergroup trial. 2012 ·Journal of Clinical Oncology ·Akiko Hisamoto, Jiichiro Sasaki, Nagio Takigawa, Yoshiyuki Shioyama, Junji Kishimoto, Mitsuhiro Takemoto, Katsuyuki Hotta, Mitsune Tanimoto, Yukito Ichinose, Katsuyuki Kiura, (unknown)	3
9	Impact of body surface area on efficacy of gefitinib in patients with non-small cell lung cancer harboring activating epidermal growth factor receptor mutation. 2012 ·Journal of Clinical Oncology ·Eiki Ichihara, Katsuyuki Hotta, Akiko Hisamoto, Nagio Takigawa, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura	1
10	Difference in incidence and pattern of salvage treatment after failure to first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy and standard cytotoxic chemotherapy in pts with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: Okayama Lung Cancer Study Group experience. 2012 ·Journal of Clinical Oncology ·Yuka Kato, Eiki Ichihara, Katsuyuki Hotta, Akiko Hisamoto, Nagio Takigawa, Naoyuki Nogami, Toshiyuki Kozuki, Kenichiro Kudo, Masahiro Tabata, Tetsu Shinkai, Mitsune Tanimoto, Katsuyuki Kiura, (unknown)	1
11	Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systemic Review 2011 ·PLoS ONE ·Katsuyuki Hotta, Katsuyuki Kiura, Yoshiro Fujiwara, Nagio Takigawa, Akiko Hisamoto, Eiki Ichihara, Masahiro Tabata, Mitsune Tanimoto	62
12	Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment. 2009 ·PubMed ·Toshio Kubo, Nagio Takigawa, Katsuyuki Kiura, (unknown), Nobuaki Ochi, (unknown), Shigeki Umemura, Akiko Hisamoto, Mitsune Tanimoto	3
13	Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung 2007 ·Lung Cancer ·Toshiyuki Kozuki, Akiko Hisamoto, Masahiro Tabata, Nagio Takigawa, Katsuyuki Kiura, Yoshihiko Segawa, Masao Nakata, Koichi Mandai, Kenji Eguchi, Hiroshi Ueoka, Mitsune Tanimoto	14
14	Point mutation of K-ras gene in cisplatin-induced lung tumours in A/J mice 2007 ·Lung Cancer ·Akiko Hisamoto, Eisei Kondo, Katsuyuki Kiura, Toshiaki Okada, Shinobu Hosokawa, (unknown), Nagio Takigawa, Masahiro Tabata, Mitsune Tanimoto	14
15	Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation 2007 ·Oncology Reports ·Katsuyuki Hotta, Masahiro Tabata, Katsuyuki Kiura, Toshiyuki Kozuki, Akiko Hisamoto, Hideki Katayama, Nagio Takigawa, Nobukazu Fujimoto, Keiichi Fujiwara, Hiroshi Ueoka, Mitsune Tanimoto	27
16	Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells 2007 ·Oncology Reports ·Nagio Takigawa, Masami Takeyama, Toshiyuki Kozuki, Takuo Shibayama, Akiko Hisamoto, Katsuyuki Kiura, Atsuhiko Tada, Katsuyuki Hotta, Shigeki Umemura, Kadoaki Ohashi, Yoshiro Fujiwara, (unknown), Eiki Ichihara, (unknown), Masahiro Tabata, Mitsune Tanimoto, Kiyoshi Takahashi	13
17	Profile of phospho-proteins according to LKB1 gene status in lung cancer cells 2005 ·Cancer Research ·Akiko Hisamoto, Eisei Kondo, Katsuyuki Kiura, Toshiaki Okada, Shinobu Hosokawa, Hideki Katayama, Kenji Nishii, Masahiro Tabata, Hiroshi Ueoka, Mitsune Tanimoto	1
18	A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer 2004 ·Lung Cancer ·Katsuyuki Hotta, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Shoichi Kuyama, Ken Satoh, Toshiyuki Kozuki, Akiko Hisamoto, Shinobu Hosokawa, Keiichi Fujiwara, Mitsune Tanimoto	7
19	Effect of gefitinib (‘Iressa’, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer 2004 ·Lung Cancer ·Katsuyuki Hotta, Katsuyuki Kiura, Hiroshi Ueoka, Masahiro Tabata, Keiichi Fujiwara, Toshiyuki Kozuki, Toshiaki Okada, Akiko Hisamoto, Mitsune Tanimoto	143
20	Human Herpes Virus-8-Negative Primary Effusion Lymphoma in a Patient with Common Variable Immunodeficiency 2003 ·Leukemia & lymphoma ·Akiko Hisamoto, Hiromichi Yamane, Akio Hiraki, Yoshinobu Maeda, Nobuharu Fujii, Kenji Sasaki, (unknown), Takashi Sasaki, Tohru Nakamura, Katsuyuki Kiura, Mitsune Tanimoto, Haruhito Kamei	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact